The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksClontarf Regulatory News (CLON)

Share Price Information for Clontarf (CLON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0375
Bid: 0.035
Ask: 0.04
Change: 0.00 (0.00%)
Spread: 0.005 (14.286%)
Open: 0.0375
High: 0.0375
Low: 0.0375
Prev. Close: 0.0375
CLON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results for the period ended 30 June 2023

25 Sep 2023 07:00

RNS Number : 4292N
Clontarf Energy PLC
25 September 2023
 

25 September 2023

Clontarf Energy plc

("Clontarf" or the "Company")

 

Interim Statement for the period ended 30 June 2023

 

Clontarf Energy plc (AIM: CLON), the energy company focused on Australia, Africa and Bolivia, announces its unaudited financial results for the six months ended 30 June 2023:

 

Highlights

 

• Formation of a comprehensive joint venture with breakthrough Direct Lithium Extraction ("DLE") technology developers NEXT-ChemX (the "JV").

 

• Brine samples from five priority salares provided by the Bolivian State Lithium Company for testing.

 

• All samples successfully navigated the US Customs checks without setbacks.

 

• The JV's pilot plant components have now largely been assembled at sub-contractor facilities.

 

• Technical improvements including development and perfection of state-of-the-art German-engineered sensors, to improve performance.

 

• Pilot plant construction, including assembly of innovative components, will shortly be underway in Texas, after which testing will begin.

 

• Subject to test results and Bolivian laws, Clontarf plans to run large-scale production testing to fine-tune the process.

 

• Under applicable laws, the JV is ready to construct mobile pilot plants to process brines at different salares in Bolivia and neighbouring countries.

 

• Clontarf has been invited to participate in European Union initiatives to deliver battery-grade lithium salts to European automotive, grid storage and mobile electronics industries.

 

• The Bolivian authorities have adopted the suggestion to conduct a bid-round on medium-sized salares, certain of which Clontarf has reviewed and sampled.

 

• Ratification discussions on Tano 2A block with Ghanaian authorities continue - though the authorities have sought to re-negotiate (to their benefit) at the acreage and fiscal terms previously agreed. A new realism seems evident.

 

• Further Australian drill targets are under consideration, especially for gas to serve the dynamic liquified natural gas ("LNG") market.

Chairman's Statement

 

Recent months have witnessed accelerated field-work on several fronts:

 

Clontarf teams have conducted further site-visits, sampling and related geological work to deepen our understanding of opportunities and challenges offered by the development of Direct Lithium Extraction technologies.

 

Our primary focus has been working with the Bolivian authorities, in accordance with applicable laws. This covers both our work on Direct Lithium Extraction technologies, in joint venture with NEXT-ChemX, as well as Clontarf's proposals to explore and develop medium-sized salares. The Bolivian authorities have now confirmed their plan to run a bid-round, as required by law and proper governance, on these high-potential though under-explored salt-lakes. This reflects a vision to develop the world's greatest lithium resource as soon as feasible, to benefit local communities, the authorities, as well as our partners, customers and the road to energy transition.

 

Our JV partners have completed financings and sub-contractor supply agreements on long-lead time and scarce components. Some components are being enhanced in order to serve anticipated as well as current customer needs. Remaining elements are being shipped to site for final assembly, commissioning and testing.

 

This progress has brought us to the attention of the EU Commission, as well as State-backed initiatives in Britain and the USA. Clontarf has been invited to participate in a drive to explore and develop lithium and other strategic minerals in northern Argentina, and possibly other jurisdictions. We believe that such timely initiatives may open larger and lower cost sources of equity and debt financings. This would cut our cost of capital and open many new opportunities for value added and expansion.

 

Subject to applicable laws, Clontarf has offered to participate in a Bolivian Lithium opportunity in partnership with YLB using DLE technology being developed by our technical partner, Next ChemX Corporation.

 

Every brine is different, and we must ensure that the processing parameters are compatible with the quantity, quality and other parameters of the minerals that are present in the particular brine. This is necessary in order to complete the design of the larger commercial pilot plant specifically made for the selected Bolivian brines.

 

With all necessary permits, we plan to collect and process larger samples for pilot plant testing, including kinetics calculations, flow-rates, etc.

 

The NEXT-ChemX process works directly from the brine, and after a quick filtering to ensure there are no solids or debris in the brine we feed into our system. We normally produce pure Lithium Chloride, which we can then convert to battery grade Li2CO3 or LiOH - or possibly Lithium metal for solid state lithium batteries.

 

This pilot plant testing will enable fine tuning of the process, and determine recovery parameters, as well as operating cost numbers applicable for different brine samples. 

 

This work will help optimise output, demonstrating the effectiveness of the Next ChemX technology and determining throughput and recovery expected at in-situ pilot plants in South America, and possibly elsewhere.

 

The mobile pilot plant will ideally run for 4 and 6 months, to assess the potential of that location, after which the mobile pilot plant can then be moved and reassembled at another salar. This approach will enable customising of the DLE process for a variety of brine grades and chemistries.

 

The Clontarf JV, in conjunction with the authorities, under applicable laws, plans to build a full scale processing plant of an agreed capacity to extract production tonnages of Lithium Carbonate, or other desired form of Lithium. We would also assess the viability for the recovery of calcium, magnesium, and potassium chlorides at each location showing attractive flow volumes and recoverable grade. The overall capacity will be scalable via deployment of modular units over a period of months to years.

 

Each plant can be upgraded to produce value added production, i.e. lithium chloride to lithium carbonate, lithium hydroxide and, if feasible, lithium metal. A similar approach to boosting value added will be implemented for other, economic non-lithium minerals, such as magnesium and potassium.

 

In oil and gas, the tightening hydrocarbons' supply-demand balance promises a long-overdue revival of exploration and the farm-out market. Shortages of piped gas and LNG feedstock have strengthened long-term prices. The centrality of LNG to fuel any energy transition in Europe and Asia has now been broadly accepted - except for fringe elements - and even by previous sceptics. There can be no reliance on intermittent renewables generation without reliable back-up.

 

The resurgence of interest in African exploration and development may lead to additional proposals in the coming months. Clontarf continues to insist on strict adherence to our ESG standards.

 

Clontarf therefore progresses its interests in Bolivia, Australia, Chad and Ghana, maintaining cordial communications with the relevant authorities, and continues to operate efficiently on minimal expenditure.

 

Funding

 

Subject to technical verification of its exploration projects, and permitting, Clontarf is confident of securing adequate funding, whether in London or Australia, for near to medium term ongoing activities.

 

We set out to reduce political and geological risks.

Fortune favours the brave. The best is yet to come.

 

 

 

 

David Horgan

Chairman

22nd September 2023

 

 

 

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

ENDS

 

 

 

For further information please visit http://clontarfenergy.com or contact:

 

 

Clontarf Energy

David Horgan, Chairman

Jim Finn, Director

+353 (0) 1 833 2833

Nominated & Financial Adviser

Strand Hanson Limited

Rory Murphy

Ritchie Balmer

+44 (0) 20 7409 3494

Broker

Novum Securities Limited

Colin Rowbury

+44 (0) 207 399 9400

Public Relations

BlytheRay

Megan Ray

+44 (0) 207 138 3206

 

Teneo

Luke Hogg

Alan Tyrrell

+353 (0) 1 661 4055

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 

 

 

Six Months Ended

Year Ended

 

30 June 23

30 June 22

31 Dec 22

 

unaudited

unaudited

audited

 

£'000

£'000

£'000

 

Administrative expenses

(288)

(414)

(672)

Impairment of exploration and evaluation assets

-

(4,095)

(4,095)

LOSS BEFORE TAXATION

(288)

(4,509)

(4,767)

Income Tax

-

-

-

COMPREHENSIVE INCOME FOR THE PERIOD

(288)

(4,509)

(4,767)

LOSS PER SHARE - basic and diluted

 (0.01p)

 (0.34p)

 (0.26p)

CONDENSED CONSOLIDATED BALANCE SHEET

 

 

 

 

 30 June 23

 30 June 22

 31 Dec 22

 

 unaudited

 unaudited

 audited

 

 £'000

 £'000

 £'000

ASSETS:

 

NON-CURRENT ASSETS

 

Intangible assets

1,756

868

868

1,756

868

868

CURRENT ASSETS

 

Other receivables

-

1

-

Cash and cash equivalents

381

188

932

 

381

189

932

TOTAL ASSETS

2,137

1,057

1,800

LIABILITIES:

 

CURRENT LIABILITIES

 

Trade and other liabilities

(1,512)

(2,088)

(3,027)

(1,512)

(2,088)

(3,027)

TOTAL LIABILITIES

(1,512)

(2,088)

(3,027)

NET ASSETS / (LIABILITIES)

625

(1,031)

(1,227)

EQUITY

 

Called-up share capital

6,209

5,927

5,927

Share premium

12,737

10,985

10,985

Share based payment reserve

354

186

248

Retained deficit

(18,675)

(18,129)

(18,387)

TOTAL EQUITY

625

(1,031)

(1,227)

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 

 Called-up

 

 Share based

 

 Share

 Share

 Payment

 Retained

 

 Capital

 Premium

 Reserves

 Deficit

 Total

 

 £'000

 £'000

 £'000

 £'000

 £'000

 

As at 1 January 2022

2,177

10,985

186

(13,620)

(272)

Shares issued

3,750

-

-

-

3,750

Total comprehensive income

 -

(4,509)

(4,509)

As at 30 June 2022

5,927

10,985

186

(18,129)

(1,031)

Share based payment charge

-

-

62

-

62

Total comprehensive income

 -

-

-

(258)

(258)

As at 31 December 2022

5,927

10,985

248

(18,387)

(1,227)

Shares issued

282

1,849

-

-

2,131

Share issue expenses

-

(97)

-

-

(97)

Share based payment charge

-

-

106

-

106

Total comprehensive income

-

-

-

(288)

(288)

As at 30 June 2023

6,209

12,737

354

(18,675)

625

 

 

CONDENSED CONSOLIDATED CASH FLOW

 Six Months Ended

 Year Ended

 

 30 June 23

 30 June 22

 31 Dec 22

 

 unaudited

 unaudited

 audited

 

 £'000

 £'000

 £'000

CASH FLOW USED IN OPERATING ACTIVITIES

 

Loss for the period

(288)

(4,509)

(4,767)

Impairment of exploration and evaluation assets

-

4,095

4,095

Share based payment charge

106

-

62

Exchange movements

2

1

3

(180)

(413)

(607)

Movements in working capital

Decrease in other receivables

-

2

2

(Decrease)/Increase in trade and other payables

(1,516)

601

1,541

 

(1,516)

603

1,543

 

NET CASH USED IN OPERATING ACTIVITIES

(1,696)

190

936

CASH FLOWS USED IN INVESTING ACTIVITIES

 

Payments for intangible assets

(406)

(4,095)

(4,095)

NET CASH USED IN INVESTING ACTIVITIES

(406)

(4,095)

(4,095)

CASH FLOW FROM FINANCING ACTIVITIES

 

Issue of shares

1,650

3,750

3,750

Share issue expenses

(97)

-

-

NET CASH GENERATED FROM FINANCING ACTIVITIES

1,553

3,750

3,750

NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS

(549)

(155)

591

Cash and cash equivalents at beginning of the period

932

344

344

Exchange loss on cash and cash equivalents

(2)

(1)

(3)

CASH AND CASH EQUIVALENT AT THE END OF THE PERIOD

381

188

932

Notes:

 

1. INFORMATION

The financial information for the six months ended 30 June 2023 and the comparative amounts for the six months ended 30 June 2022 are unaudited. The financial information above does not constitute full statutory accounts within the meaning of section 434 of the Companies Act 2006.

 

The Interim Financial Report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the U.K. The accounting policies and methods of computation used in the preparation of the Interim Financial Report are consistent with those used in the Group 2022 Annual Report, which is available at www.clontarfenergy.com

 

The interim financial statements have not been audited or reviewed by the auditors of the Group pursuant to the Auditing Practices board guidance on Review of Interim Financial Information.

 

2. DIVIDEND

No dividend is proposed in respect of the period.

3. GOING CONCERN

The Group incurred a loss for the period of £288,472 (2022: £4,766,646) and had net current liabilities of £1,130,220 (2022: £2,094,612) at the balance sheet date. These conditions, as well as those noted below, represent a material uncertainty that may cast doubt on the Group's ability to continue as a going concern.

 

Included in current liabilities is an amount of £1,450,565 (2022: £1,525,565) owed in respect of Directors' remuneration due at the balance sheet date. The Directors have confirmed that they will not seek settlement of these amounts in cash until after the end of 2024.

 

The Group had a cash balance of £381,420 (2022: £931,902) at the balance sheet date. As the Group is not revenue or cash generating it relies on raising capital from the public market. On 16 January 2023 the Group raised £1,300,000 on a placing and a further £350,000 on 1 June 2023. Further information is detailed in Note 7 below.

 

As in previous years the Directors have given careful consideration to the appropriateness of the going concern basis in the preparation of the financial statements and believe the going concern basis is appropriate for these financial statements. The financial statements do not include the adjustments that would result if the Group and Company were unable to continue as a going concern.

 

4. LOSS PER SHARE

Basic loss per share is computed by dividing the loss after taxation for the year attributable to ordinary shareholders by the weighted average number of ordinary shares in issue and ranking for dividend during the year. Diluted earnings per share is computed by dividing the loss after taxation for the year by the weighted average number of ordinary shares in issue, adjusted for the effect of all dilutive potential ordinary shares that were outstanding during the year.

 

The following table sets out the computation for basic and diluted earnings per share ("EPS"):

 

Six Months Ended

Year Ended

30 June 23

30 June 22

31 Dec 22

£'000

£'000

£'000

 

Loss for the year attributable to equity holders

(288)

(4,509)

(4,767)

Denominator

Number

Number

Number

For basic and diluted EPS 

4,385,660,371

1,328,908,309

1,856,031,596

Basic and diluted EPS

(0.01p)

(0.34p)

(0.26p)

 

Basic and diluted loss per share are the same as the effect of the outstanding share options is anti-dilutive and is therefore excluded.

 

5. INTANGIBLE ASSETS

 

30 June 23

30 June 22

31 Dec 22

£'000

£'000

£'000

Exploration and evaluation assets

Cost:

At 1 January

12,735

8,640

8,640

Additions

888

4,095

4,095

Closing Balance

13,623

12,735

12,735

Impairment:

At 1 January

11,867

7,772

7,772

Provision for impairment

-

4,095

4,095

Closing Balance

11,867

11,867

11,867

Carrying value:

At 1 January

868

868

868

At period end

1,756

868

868

 

 

 

 

 

Regional Analysis

30 Jun 23

£'000

30 Jun 22

£'000

31 Dec22

£'000

Bolivia - Investment in JV

888

-

-

Ghana

868

868

868

1,756

868

868

 

 

Exploration and evaluation assets relate to expenditure incurred in prospecting and exploration for lithium, oil and gas in Bolivia and Ghana. The Directors are aware that by its nature there is an inherent uncertainty in exploration and evaluation assets and therefore inherent uncertainty in relation to the carrying value of capitalised exploration and evaluation assets.

 

During 2018 the Group resolved the outstanding issues with the Ghana National Petroleum Company ("GNPC") regarding a contract for the development of the Tano 2A Block. The Group has signed a Petroleum Agreement in relation to the block and this agreement awaits ratification by the Ghanian government.

 

The Company is in negotiations with the Vice-Ministry of Electrical Technologies and the State Lithium Company in Bolivia on exploration and development of salt-lakes in accordance with law. Samples have been analysed and process work is underway.

 

On 15 February 2023 the Company announced a heads of agreement around the potential formation of a 50:50 Joint Venture with US based, OTC Markets traded, technology company, NEXT-ChemX Corporation ("NCX") covering testing, marketing, and deploying of NCX's proprietary (patent pending) direct lithium ion extraction ("DLE") technology in Bolivia. Formation of the JV was subject to final due diligence and the parties entering into formal documentation.

 

On 5 May 2023 the Company announced that all conditions precedent had been satisfied with respect to the JV with NEXT-ChemX coming into force. In this regard, Clontarf paid NEXT-ChemX Corporation US$500,000 and has issued to NEXT-ChemX 385 million new Ordinary Shares in the capital of Clontarf of which half are subject to a 12-month lock in requirement.

 

The Directors believe that there were no facts or circumstances indicating that the carrying value of intangible assets may exceed their recoverable amount and thus no impairment review was deemed necessary by the Directors. The realisation of these intangibles assets is dependent on the successful discovery and development of economic deposit resources and the ability of the Group to raise sufficient finance to develop the projects. It is subject to a number of potential significant risks, as set out below.

 

The Group's activities are subject to a number of significant potential risks including:

 

· licence obligations;

· exchange rate risks;

· uncertainties over development and operational costs;

· political and legal risks, including agreements with Governments for licences, profit sharing and taxation;

· foreign investment risks including increases in taxes, royalties and renegotiation of contracts;

· title to assets;

· financial risk management;

· going concern; and

· ability to raise finance.

 

6. TRADE AND OTHER PAYABLES

 

30 June 23

30 June 22

31 Dec 22

£'000

£'000

£'000

Creditor - Western Gas

-

550

553

Trade payables

35

48

57

Other payables

1,451

1,480

1,526

Cash received in advance of share placing

-

-

870

Related parties

13

-

5

Other accruals

12

10

16

1,511

2,088

3,027

 

Other payables relate to amounts due to Directors and a former Director for remuneration accrued but not paid at period end.

 

7. SHARE CAPITAL

Deferred Shares - nominal value of 0.24p

 

 

 

Number

 

Share Capital

£'000

Share Premium

£'000

At 1 January 2022

-

-

-

At 30 June 2022

-

-

-

Transfer from ordinary shares

2,370,826,117

5,690

-

At 31 December 2022 and 30 June 2023

2,370,826,117

5,690

-

Ordinary Shares - nominal value of 0.01p

Allotted, called-up and fully paid:

 

 

 

Number

Share Capital

Share Premium

 

 

£'000

£'000

 

 

 

 

At 1 January 2022

870,826,117

2,177

10,985

Issued during the period

1,500,000,000

3,750

-

At 30 June 2022

2,370,826,117

5,927

10,985

 

 

Transfer to deferred shares

 

(5,690)

-

At 31 December 2022

2,370,826,117

237

10,985

Issued during the period

2,822,500,000

282

1,849

Share issue expenses

-

-

(97)

At 30 June 2023

5,193,326,117

519

12,737

 

 

 

 

On 4 August 2022 the 2,370,826,117 issued ordinary shares of 0.25p each were subdivided via ordinary resolution into 2,370,826,117 ordinary shares of 0.01p each and 2,370,826,117 deferred shares of 0.24p each.

 

Movements in issued share capital

 

On 16 January 2023 the Company raised £1,300,000 via a placing of 2 billion new ordinary shares of 0.01p each, via several Australian based brokers, at a price of 0.065p per share. In connection with the placing 97,500,000 warrants were issued to the brokers involved in the placing. Further information is detailed in Note 8 below. The proceeds were used to advance the Company's lithium projects in Bolivia, and petroleum projects in Ghana, Australia, and elsewhere.

 

On 5 May 2023 as part of the Joint Venture agreement with NEXT-ChemX the Company issued 385 million ordinary shares of 0.01p each at a price of 0.125p to NEXT-ChemX. Further information is detailed in Note 5 above.

 

On 1 June 2023 the Company raised £350,000 via a placing of 437,500,000 ordinary shares of 0.01p each at a price of 0.08p per share. Proceeds raised will be used to provide additional working capital and fund developments costs.

 

8. SHARE BASED PAYMENTS

 

SHARE OPTIONS

 

The Group issues equity-settled share-based payments to certain Directors and individuals who have performed services for the Group. Equity-settled share-based payments are measured at fair value at the date of grant.

 

Fair value is measured by the use of a Black-Scholes model.

 

The Group plan provides for a grant price equal to the average quoted market price of the ordinary shares on the date of grant.

 

 

30 Jun 23

30 Jun 22

31 Dec22

 

Options Number

'000

Weighted average exercise price in pence

Options Number

'000

Weighted average exercise price in pence

Options Number

'000

Weighted average exercise price in pence

At 1 January

40,500

0.7

40,500

0.7

40,500

0.7

Issued

160,000

0.0725

-

-

Outstanding at end of period

200,500

0.20

40,500

0.7

40,500

0.7

Exercisable at end of period

200,500

0.20

30,500

0.7

40,500

0.7

 

On 17 January 2023 a total of 160,000,000 options were granted with a fair value of £106,632 to Directors and individuals who have performed services for the Group. These fair values were calculated using the Black-Scholes valuation model.

 

The inputs into the Black-Scholes valuation model were as follows:

 

Grant 17 January 2023

Weighted average share price at date of grant (in pence) 0.07p

Weighted average exercise price (in pence) 0.0725p

Expected volatility 144.39%

Expected life 7 years

Interest free rate 5%

Expected dividends none

 

Expected volatility was determined by management based on their cumulative experience of the movement in share prices. The terms of the options granted do not contain any market conditions within the meaning of IFRS 2.

 

The Group capitalised expenses of £Nil (2022: £Nil) and expensed costs of £106,632 (2022: £61,695) relating to equity-settled share-based payment transactions during the year.

 

Warrants

 

 

30 Jun 23

30 Jun 22

31 Dec22

 

Warrants

Number

'000

Weighted average exercise price in pence

Warrants Number

'000

Weighted average exercise price in pence

Warrants

Number

'000

Weighted average exercise price in pence

At 1 January

435,683

0.25

-

-

-

-

Issued

97,500

0.065

435,683

0.25

435,683

0.25

Exercisable at end of period

533,183

0.22

435,683

0.25

435,683

0.25

 

On 16 January 2023 in connection with the share placing a total of 97,500,000 warrants were issued to the brokers involved with the placing. The warrants have an exercise price of 0.065p.

 

9. POST BALANCE SHEET EVENTS

 

On 1 August 2023 the Company announced that the following long-term, incentive share options have been granted over, in aggregate, 300,000,000 ordinary shares of 0.01p each in the Company. The Options vest immediately, have an exercise price of 0.10p and an expiry date of 30th July 2030. 

 

The Options have been awarded as follows:

 

 

Number of Options Granted

David Horgan

115,000,000

James Finn

75,000,000

Peter O'Toole

75,000,000

Dipti Mehta

35,000,000

 

 

10. The Interim Report for the six months to 30 June 2023 was approved by the Directors on 22 September 2023.

 

 

11. The Interim Report will be available on the Company's website at www.clontarfenergy.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR PPUUUBUPWGMP
Date   Source Headline
10th Apr 20241:35 pmRNSGrant of Share Options
18th Mar 20247:00 amRNSBolivia Update, Fundraising and TVR
6th Mar 202410:33 amRNSEncouraging Bolivian Brines Progress
5th Feb 20247:00 amRNSSouth American Brines Progress
25th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
1st Aug 202310:38 amRNSGrant of Share Options
13th Jul 202312:35 pmRNSResult of AGM and Corporate Update
22nd Jun 202312:32 pmRNSPosting of Annual Report and Notice of AGM
8th Jun 20237:00 amRNSPreliminary Results
1st Jun 20237:00 amRNS£350,000 Fundraising and Corporate Update
5th May 20237:00 amRNSUpdate on Joint Venture Agreement and TVR
28th Mar 202310:24 amRNSJV Agreement on Direct Lithium Extraction Bolivia
17th Feb 202311:05 amRNSSecond Price Monitoring Extn
17th Feb 202311:00 amRNSPrice Monitoring Extension
15th Feb 20237:00 amRNSJV HoA on Direct Lithium Ion Extraction in Bolivia
17th Jan 202310:34 amRNSGrant of Share Options
16th Jan 20237:00 amRNS£1.3 million Fundraising and Corporate Update
8th Nov 20224:40 pmRNSSecond Price Monitoring Extn
8th Nov 20224:35 pmRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results for the period ended 30 June 2022
5th Sep 20227:02 amRNSShare Price Movement and Shareholder Update
4th Aug 20221:00 pmRNSResult of AGM and Capital Reorganisation
1st Jul 202211:04 amRNSDirector Change
29th Jun 202210:30 amRNSPosting of Annual Report
22nd Jun 20227:00 amRNSPreliminary Results for the Year Ended 31 Dec 2021
14th Jun 20227:00 amRNSSasanof-1 well completion
6th Jun 20227:00 amRNSSasanof-1 well final result
6th Jun 20227:00 amRNSResult of General Meeting
30th May 20228:00 amRNSSasanof-1 well drilling update
27th May 20227:00 amRNSSasanof-1 well spudding
23rd May 20227:00 amRNSSasanof-1 well mobilisation update
20th May 20224:41 pmRNSSecond Price Monitoring Extn
20th May 20224:36 pmRNSPrice Monitoring Extension
18th May 20222:06 pmRNSSecond Price Monitoring Extn
18th May 20222:00 pmRNSPrice Monitoring Extension
18th May 20227:00 amRNSSasanof-1 well mobilisation update
17th May 202211:00 amRNSPrice Monitoring Extension
12th May 202211:53 amRNSUpdate on Sasanof-1 well
11th May 20223:58 pmRNSNotice of General Meeting
10th May 20227:00 amRNSConsideration Shares to be Admitted to Trading
9th May 20227:00 amRNSAcquisition of 10% of Sasanof Prospect
27th Apr 20221:02 pmRNSPlacing to raise £3,500,000
12th Jan 20224:40 pmRNSIssue of Warrants and RPT
20th Sep 20214:41 pmRNSSecond Price Monitoring Extn
20th Sep 20214:36 pmRNSPrice Monitoring Extension
15th Sep 20217:00 amRNSInterim Statement
23rd Jun 202111:35 amRNSResult of Annual General Meeting and Board Changes
7th Jun 202110:50 amRNSPosting of Annual Report and Notice of AGM
24th May 20214:11 pmRNSTR-1: Notification of major holdings
20th May 20213:58 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.